Parametric Portfolio Associates’s Ascendis Pharma A/S ASND Stock Holding History

Parametric Portfolio Associates’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$2.2M	Sell	18,743 -14,357	-43%	-$1.66M	﹤0.01%	2375
2021 Q4	$4.45M	Buy	33,100 +5,509	+20%	+$819K	﹤0.01%	1947
2021 Q3	$4.4M	Buy	27,591 +26	+0.1%	+$3.56K	﹤0.01%	1925
2021 Q2	$3.63M	Buy	27,565 +7,620	+38%	+$1.02M	﹤0.01%	2075
2021 Q1	$2.57M	Buy	19,945 +756	+4%	+$115K	﹤0.01%	2616
2020 Q4	$3.2M	Buy	19,189 +9,107	+90%	+$1.51M	﹤0.01%	2369
2020 Q3	$1.56M	Buy	10,082 +807	+9%	+$116K	﹤0.01%	2654
2020 Q2	$1.37M	Buy	9,275 +2,270	+32%	+$312K	﹤0.01%	2738
2020 Q1	$789K	Buy	7,005 +4,311	+160%	+$560K	﹤0.01%	2927
2019 Q4	$375K	Sell	2,694 -3,064	-53%	-$340K	﹤0.01%	3479
2019 Q3	$555K	Buy	5,758 +2,122	+58%	+$237K	﹤0.01%	3306
2019 Q2	$419K	Buy	3,636 +1,233	+51%	+$148K	﹤0.01%	3433
2019 Q1	$283K	Sell	2,403 -999	-29%	-$87.5K	﹤0.01%	3571
2018 Q4	$213K	Buy	+3,402	New	+$214K	﹤0.01%	3641

Other funds holding ASND

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Parametric Portfolio Associates's ASND Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Ascendis Pharma A/S (ASND) stake by 43% in Q1 2022, selling an estimated $1.66M and leaving 18,743 shares worth $2.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

Parametric Portfolio Associates first reported a position in ASND in Q4 2018 and has held it in 14 quarters since. The position peaked at $4.45M in Q4 2021. 177 funds tracked by Wall St. Rank hold ASND as of Q1 2022.

Parametric Portfolio Associates held 18,743 shares of Ascendis Pharma A/S worth $2.2M as of Q1 2022.
Parametric Portfolio Associates sold 14,357 Ascendis Pharma A/S shares in Q1 2022, an estimated $1.66M.
Ascendis Pharma A/S made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2375 holding.
Parametric Portfolio Associates first reported a position in Ascendis Pharma A/S in Q4 2018 and has held it in 14 quarters since.
Parametric Portfolio Associates's Ascendis Pharma A/S position peaked at $4.45M in Q4 2021.
177 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.